AbbVie (ABBV) Net Cash Flow (2012 - 2026)

AbbVie has disclosed Net Cash Flow across 15 years of filings, most recently posting $4.2 billion for Q1 2026.

• In Q1 2026, Net Cash Flow rose 1265.92% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (up 132.64% YoY), while the FY2025 annual figure was -$337.0 million, up 95.34% from the prior year.
• Net Cash Flow rose to $4.2 billion in Q1 2026, from -$411.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for ABBV reached as high as $5.3 billion in Q1 2024 and fell as low as -$5.9 billion in Q3 2024.
• The 5-year median for Net Cash Flow is -$411.0 million (2025), against an average of -$15.5 million.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 368.55% — and 2026, when it surged 1265.92%.
• A 5-year view of Net Cash Flow shows it stood at -$2.7 billion in 2022, then jumped by 81.31% to -$496.0 million in 2023, then tumbled by 240.12% to -$1.7 billion in 2024, then jumped by 75.64% to -$411.0 million in 2025, then surged by 1115.57% to $4.2 billion in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $4.2 billion, -$411.0 million, and -$830.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.